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Available online 10 September 2016Abstract We recently reported that PIK3CAmutant colorectal cancers (CRCs) are addicted to
glutamine through up-regulation of glutamate pyruvate transaminase 2 (GPT2). A GPT2 inhib-
itor suppresses in vivo growth of PIK3CA mutant, but not wild-type, CRCs. This study indicates
that targeting glutamine may be an effective approach to treat CRCs with PIK3CA mutations.
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an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Metabolic reprogramming is a hallmark of cancer.1 It has
long been known that most cancer cells are dependent on
glutamine to grow. Although glutamine is a non-essential
amino acid, it is a required supplement for culturing can-
cer cells. In addition to being used as a building block for
protein, glutamine can also be utilized as a fuel source to
replenish the tricarboxylic acid (TCA) cycle. In this process,
glutamine is first converted to glutamate by glutaminases
(GLSs), followed by conversion to a-ketoglutarate (a-KG), a
TCA cycle intermediate (Fig. 1). The conversion from
glutamate to a-KG is mediated by either transaminases or
glutamate dehydrogenases. Recent studies showed that
many oncogenes and tumor suppressor genes are involved
in glutamine metabolism. PIK3CA, which encodes the p110a* Corresponding author.
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is the most frequently mutated oncogene in human cancers
including 20e30% of colorectal cancers (CRCs).2,3 However,
whether mutant PIK3CA/p110a reprograms cancer meta-
bolism was an important unaddressed question.
Using isogenic CRC cell lines with either the wild type
(WT) or mutant alleles of PIK3CA knocked out, we demon-
strated that PIK3CA mutations render CRCs more addicted
to glutamine, but not glucose.4 To our knowledge, this is
the first study to demonstrate that specific oncogenic mu-
tations render cancer cells differentially sensitive to
glutamine deprivation. Although it has been previously
shown that WT KRAS regulates glutamine metabolism in
pancreatic cancers,5 it is not clear that oncogenic KRAS
mutations render cancer cells more sensitive to glutamine
deprivation. Moreover, our study clearly demonstrated that
KRAS mutations do not make colorectal cancers more
dependent on glutamine, because isogenic KRAS mutant
and WT CRC clones do not show differential sensitivity to
glutamine deprivation.4and hosting by Elsevier B.V. This is an open access article under the
4.0/).
Fig. 1 Oncogenic PIK3CA mutations reprogram glutamine
metabolism by up-regulating GPT2. As a fuel source, gluta-
mine is first converted to glutamate and then a-KG to replenish
the tricarboxylic acid (TCA) cycle. Oncogenic p110a mutant
protein reprograms glutamine metabolism through upregula-
tion of GPT2. A pan-aminotransferase inhibitor AOA suppresses
xenograft tumor growth of PIK3CA mutant, but not wild type
(WT), CRCs. GLS: glutaminase; GPT2: glutamate pyruvate
transaminase 2; a-KG: a-ketoglutarate; AOA:
aminooxyacetate.
242 CommentaryMechanistically, mutant PIK3CA/p110a up-regulates
mitochondrial glutamate pyruvate transaminase 2 (GPT2)
and therefore converts more glutamate to a-KG to
replenish the TCA cycle,4 which generates more ATP and
macromolecules to sustain rapid tumor growth. Although
AKT is a well-known downstream mediator of the PI3K
signaling, mutant p110a up-regulates GPT2 gene expression
by an AKT independent pathway. Mutant p110a activates
RSK2 kinase through PDK1.4 Activated RSK2 then phos-
phorylates ATF4 at the serine residue 245, which in turn
recruits the deubiquitinase USP8 and protects ATF4 from
ubiquitin-mediated degradation.4 Accumulation of ATF4
enhances GPT2 gene expression. Therefore, our study
revealed a novel p110aePDK1eRSK2eATF4eGPT2 signaling
axis that reprograms glutamine metabolism.
Our study has important therapeutic implications.
Despite huge efforts made by both pharmaceutical com-
panies and academic institutions in last ten years, only a
couple of p110a-specific inhibitors have been developed.
Early clinical trials of the Novartis p110a-specific inhibitor,
BYL719, indicate that BYL719 alone induced partial re-
sponses in cancer patients harboring PIK3CA mutations.6
Recent studies showed that cancers quickly develop resis-
tance to BYL719 by loss of PTEN or up-regulation of AXL.7
Therefore, alternative approaches are urgently needed to
target PIK3CA mutations in patients. We demonstrated that
aminooxyacetate (AOA), a compound that targets gluta-
mine metabolism by blocking conversion of glutamate to a-
KG (Fig. 1), effectively inhibits xenograft tumor growth of
four colorectal cancer cell lines harboring PIK3CA muta-
tions.4 In contrast, AOA has no effect on the growth of
xenograft tumors established from two colorectal cancercell lines with WT PIK3CA.4 Although AOA is a pan-
aminotransferase inhibitor, our data clearly demonstrate
that the tumor inhibitory effect of AOA on PIK3CA mutant
xenografts is indeed on-target to GPT2, because GPT2
knockdown cells grow much slower in nude nice and these
tumors are insensitive to AOA treatment.4 It is conceivable
that a GPT2-specific inhibitor could be more potent and less
toxic. Our current effort is devoted to develop potent and
specific GPT2 inhibitor by performing a high throughput
compound screening campaign and chemically modifying
the lead compound AOA.
Lastly, our study suggest that PIK3CA mutations may
serve as a predictive biomarker for drugs that target
glutamine metabolism. Predictive markers are critical tools
to guide successful clinical trials and effective treatment of
cancer patients. For example, in lung cancer, only patients
with EGFR mutations respond to EGFR-inhibitor treatment,
whereas in colon cancers acquired KRAS mutations predict
resistance to anti-EGFR antibody therapies. These markers
provide valuable tools for guiding the choice of cancer
therapies. Increasing evidence indicates that targeting
glutamine metabolism could be an effective cancer ther-
apy. Many preclinical studies demonstrated that targeting
glutamine metabolism effectively inhibits tumor growth of
a variety of human cancers.8 Several compounds that target
glutamine metabolism pathways are under development. In
fact, phase I clinical trials have been undertaken for a
compound (CB-839) that inhibits glutaminase.9 A key
question is how to better select cancer patients to be
treated with drugs that target glutamine metabolism. Our
unpublished data demonstrated that CB-839 also inhibits
xenograft tumor growth of PIK3CA mutant CRCs, but not
PIK3CA WT CRCs, suggesting that PIK3CA mutations may
serve as a biomarker to predict patients who respond to
drugs targeting glutamine metabolism.
In summary, implications of our study are three-fold: (1)
shed new lights into the mechanisms by which PIK3CA mu-
tations drive colorectal tumorigenesis through reprogram-
ming glutamine metabolism; (2) identify GPT2 as a drug
target for CRCs with PIK3CA mutations; and (3) indicate
PIK3CA mutation as a predictive biomarker for drugs tar-
geting glutamine metabolism. Future studies are warranted
to pursue these exciting directions.Acknowledgement
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